ESMO 2018: Cabozantinib in combination with atezolizumab in metastatic kidney cancer

The following video interview from Practice Update discusses the promising results from the phase 1b trial of cabozantinib in combination with atezolizumab for metastatic renal cell carcinoma (RCC), the results of which were presented at the European Society of Medical Oncology (ESMO) conference in Munich, Germany last week.

Watch the video interview from Practice Update here

Share this Post!

Related post